The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia.
Overproduction of very low-density lipoprotein apolipoprotein B by the liver is a metabolic marker for familial combined hyperlipidaemia, a common inherited disorder of lipoprotein metabolism. Four subjects with familial combined hyperlipidaemia had rates of apolipoprotein B production which were 2-7 times normal, using a protocol in which [15N]glycine was used to label newly synthesized hepatic proteins. Following 4-6 months of therapy with lovastatin, very low-density lipoprotein apolipoprotein B production in all four subjects had returned to the normal range. This demonstrates that lovastatin, an inhibitor of cholesterol biosynthesis, acts also to reduce the apparent production rate of apolipoprotein B by the liver.
Cortner
J A
JA
Lipid-Heart Research Center, Children's Hospital of Philadelphia, Pennsylvania.
Bennett
M J
MJ
Le
N A
NA
Coates
P M
PM
D000328:Adult; D001055:Apolipoproteins B / Q000096:biosynthesis*; D005998:Glycine / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008049:Lipase / Q000378:metabolism; D008066:Lipolysis / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000096:biosynthesis*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged
D001055:Apolipoproteins B; D008079:Lipoproteins, VLDL; D006493:Heparin; D008148:Lovastatin; D008049:Lipase; D005998:Glycine